Lateral ankle sprains (LAS) are the most common injury in sports. They are especially prevalent in indoor sports, where high shoe-surface friction is considered a risk factor for “non-contact” injuries. Spraino® is a novel product that minimizes friction on the lateral edge of the shoe, thereby potentially mitigating the risk.
Materials and Methods We designed and conducted an outcome-assessor-blinded, parallel-group, two-arm pilot RCT (NCT03311490). 510 sub-elite indoor sport athletes with a history of LAS injuries were randomly allocated (1:1) to Spraino® or to a “do-as-usual” control group. The allocation procedure was concealed to investigators and participants. Match and training exposure, LAS injuries and time-loss data were captured via weekly text messages. Specifically, the objective was to determine preliminary effect (rate and severity) and safety (harms) of Spraino® when used to prevent LAS injuries among indoor sport athletes.
480 participants completed the trial, reporting a total of 151 LAS injuries. 96 were categorized as non-contact, of which 34 were severe. Incidence rate ratios of 0.87 (95% CI, 0.62-1.23) for all LAS injuries, 0.64 (95% CI, 0.42-0.97) for non-contact LAS injuries, and 0.41 (95% CI, 0.19-0.89) for severe non-contact LAS injuries were computed; all outcomes favoured Spraino®. The time-loss ratio for the total number of injuries was 0.65 (95% CI, 0.45-0.93). Six participants reported minor harm related to slipping because of Spraino®.
Spraino® was associated with a lower rate of non-contact LAS injury, lower time-loss, and with few reports of harms. Findings should be replicated in a confirmatory RCT.
|Publication date||31 Jan 2020|
|Publication status||Published - 31 Jan 2020|
|Event||Scandinavian Sports Medicine Congress: #Sportskongres - Radisson Blu Scandinavia, Copenhagen, Denmark|
Duration: 30 Jan 2020 → 1 Feb 2020
Conference number: 2020
|Conference||Scandinavian Sports Medicine Congress|
|Location||Radisson Blu Scandinavia|
|Period||30/01/2020 → 01/02/2020|